Monopar Therapeutics (MNPR) Operating Expenses (2017 - 2025)

Monopar Therapeutics has disclosed Operating Expenses across 9 years of filings, most recently posting $4.1 million for Q3 2025.

• Operating Expenses for Q3 2025 came in at $4.1 million, up 159.89% year-over-year; the trailing twelve-month figure through Dec 2025 was $10.5 million (up 75.65% YoY), and the FY2024 annual result was $4.0 million, changed N/A from the prior year.
• Operating Expenses came in at $4.1 million for Q3 2025 at Monopar Therapeutics, up from $3.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $4.1 million in Q3 2025 to a low of $918634.0 in Q4 2024.
• The 5-year median for Operating Expenses is $2.4 million (2022), against an average of $2.4 million.
• Across the five-year window, Operating Expenses tumbled 31.75% in 2024 and jumped 159.89% in 2025, its largest moves.
• Monopar Therapeutics' Operating Expenses stood at $2.7 million in 2021, then advanced by 8.5% to $2.9 million in 2022, then retreated by 28.98% to $2.1 million in 2023, then sank by 55.54% to $918634.0 in 2024, then soared by 345.56% to $4.1 million in 2025.
• The last three Operating Expenses figures came in at $4.1 million (Q3 2025), $3.2 million (Q2 2025), and $3.2 million (Q1 2025), per Business Quant data.